These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18035962)

  • 41. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong.
    Chan TH; Ho SS; Lai CK; Cheung SW; Chan RC; Cheng AF; Chan CH
    Chemotherapy; 1996; 42(2):150-6. PubMed ID: 8697891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.
    Ilowite J; Spiegler P; Kessler H
    Drugs; 2009; 69(4):407-19. PubMed ID: 19323585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosis and management of bronchiectasis.
    Smith MP
    CMAJ; 2017 Jun; 189(24):E828-E835. PubMed ID: 28630359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of exacerbations in patients with stable non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis of pharmacological and non-pharmacological therapies.
    Abu Dabrh AM; Hill AT; Dobler CC; Asi N; Farah WH; Haydour Q; Wang Z; Benkhadra K; Prokop LJ; Murad MH
    BMJ Evid Based Med; 2018 Jun; 23(3):96-103. PubMed ID: 29678900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of antibiotics in bronchiectasis.
    King PT; Holmes PW
    Rev Recent Clin Trials; 2012 Feb; 7(1):24-30. PubMed ID: 22023177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.
    Chorepsima S; Kechagias KS; Kalimeris G; Triarides NA; Falagas ME
    Drug Des Devel Ther; 2018; 12():4059-4066. PubMed ID: 30568427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacological treatment of bronchiectasis.
    Melani AS; Lanzarone N; Rottoli P
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):245-258. PubMed ID: 29268637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paediatric chronic suppurative lung disease: clinical characteristics and outcomes.
    Goyal V; Grimwood K; Marchant JM; Masters IB; Chang AB
    Eur J Pediatr; 2016 Aug; 175(8):1077-84. PubMed ID: 27287408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review.
    Brodt AM; Stovold E; Zhang L
    Eur Respir J; 2014 Aug; 44(2):382-93. PubMed ID: 24925920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnosis and treatment of bronchiectasis].
    van Haren EH; Mannes GP
    Ned Tijdschr Geneeskd; 2004 Jan; 148(3):120-5. PubMed ID: 14964021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New therapies for the prevention and treatment of exacerbations of bronchiectasis.
    Abo-Leyah H; Chalmers JD
    Curr Opin Pulm Med; 2017 May; 23(3):218-224. PubMed ID: 28212153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use.
    Goldman N; Loebinger MR; Wilson R
    Expert Rev Respir Med; 2016 Dec; 10(12):1259-1268. PubMed ID: 27820964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
    Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
    JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in bronchiectasis.
    Sapru K; Hill AT
    Clin Med (Lond); 2019 May; 19(3):230-233. PubMed ID: 31092516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunity and bacterial colonisation in bronchiectasis.
    Whitters D; Stockley R
    Thorax; 2012 Nov; 67(11):1006-13. PubMed ID: 21933944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch Teaching Hospital.
    Altenburg J; Wortel K; van der Werf TS; Boersma WG
    Neth J Med; 2015 May; 73(4):147-54. PubMed ID: 25968285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.
    Wilson CB; Jones PW; O'Leary CJ; Hansell DM; Cole PJ; Wilson R
    Eur Respir J; 1997 Aug; 10(8):1754-60. PubMed ID: 9272915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Management of bronchiectasis antibiotic therapy excepted. Non-antibiotic therapy of children and adults].
    Kalendarov D; Hubert D
    Rev Pneumol Clin; 2001 Sep; 57(4 Pt 2):S31-5; discussion S35-6. PubMed ID: 11887437
    [No Abstract]   [Full Text] [Related]  

  • 60. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis.
    Rubin BK
    J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):71-6. PubMed ID: 18518833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.